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mortality was not signiﬁcant during either follow-up window (30-day
p ¼ 0.249; 1-year p ¼ 0.253; see Figure), but showed a trend to higher
mortality in patients with very low BSA.
CONCLUSIONS No signiﬁcant association between BSA and mortality
after TAVR was detected. While there was a trend towards increased
mortality in patients with lower BSA, larger studies are needed to
provide deﬁnitive answers. As with BMI, BSA might be of prognostic
value for patients undergoing TAVR.
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BACKGROUND Valve types for transcatheter aortic valve implanta-
tion (TAVI) have undergone rapid evolution. The new balloon-
expandable Edwards Sapien-3 (S3) valve offers several novel features
to prevent or reduce typical TAVI-related problems such as para-
valvular leaks (PVLs) and vascular complications. The aim of this
study was to investigate the potential differences in the clinical
outcome compared to its predecessor Sapien XT (SXT).
METHODS We analyzed n¼400 consecutive patients undergoing TAVI
at our institution from 2012-2015 using balloon-expandable Edwards
Sapien-3 (n¼200, 61% transfemoral (TF), 27.5% transaortic (TAo), 11.5%
transapical (TA)) and Sapien XT (n¼200, 52.5% TF, 27.5% TAo and
20.0% TA) prostheses. The change in valve type was in 02/2014. All
patients were available for complete retrospective analyses. The
severity of paravalvular AR was evaluated with echocardiography 7d
after TAVI. The outcomewas analyzed according to the VARC-2 criteria.
RESULTS Comparison of both baseline characteristics of both groups
showedahigher surgical risk score for theSapien-3 group (meanSTS score S3
8.6% % (7.1) vs SXT 6.4% % (4.1)) and a higher rate of previous cardiac
surgery in SXT group (S3 30.0% vs. SXT 48.5%, p<0.001). No differences
between groups could be detected in mean age, sex, previous pacemaker
implantations, LV function, cardiovascular risk factors, COPD, and pAVK.
Despite higher surgical risk of the S3patientswe couldnot detect a difference
in 30dmortality betweenboth groups (S3 7.5%vs. SXT7.0%). Postprocedural
echocardiographyrevealed lessmildandmoderatePVLs inS3 (0%moderate,
18.8%mild AR) patients than SXT patients (4.6%moderate and 40.8%mild,
p<0.001). In addition, postdilatationwas carried outmore frequently in SXT
patients (46.0% pts vs. 23.0% pts, p<0.001). However, the use of the S3
prosthesiswasassociatedwith increased risk fornewconductiondisturbance
requiring new pacemaker implantation (S3 10.8% vs. SXT 5.2%, p¼0.05).
CONCLUSIONS Theseﬁndings indicate that theuseof theEdwardsSapien-
3device leads to reducednumbersof signiﬁcantPVLs.Yetwecoulddetect an
increased need for new pacemaker implantation in S3 patients. Future in-
vestigations aim to analyze the potential effects on long-term survival.
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BACKGROUND Direct transcatheter aortic valve implantation (TAVI)
has shown to be safe and feasible with a similar success rate to TAVI
with prior balloon aortic valvuloplasty (BAV). The aim of this study
was to evaluate the effect of direct TAVI on long-term mortality with a
self-expanding bioprosthesis.
METHODS Prospectively collected data before and after TAVI from
two high-volume centers were retrospectively analyzed in all pa-
tients. Primary clinical end-point was all-cause mortality at 1 year. All
outcomes were evaluated according to the VARC-2 criteria.
RESULTS We included 210 patients in the study (120 patients for non-
direct TAVI and 90patients for direct TAVI). Both groups had similar 1-year
mortality rates (15% in non-direct versus 11% in direct, p¼0.5). No major
differenceswereobserved concerning cardiovascular death (3%versus 2%,
p¼0.9), stroke (3% versus 5%, p¼0.4) and acute myocardial infarction (2%
versus0%, p¼0.2), in non-direct anddirect TAVI groups respectively in the
mid-term. The direct grouphad lessmoderate/severe paravalvular leakage
(PVL) post TAVI compared to the non-direct group (8% vs 27%, p<0.01). At
univariate analysis, predictors formortalitywere: BAVbefore TAVI (p¼0.2,
OR: 1.71, 95%CI: 0.742-3.939), logEuroscore (p<0.044, OR: 1.046, 95%CI:
1.001-1.093), failure to achieve device success (p¼0.143, OR: 1.795, 95%CI:
0.821-3.926) and the interventricular septum thickness (p<0.048, OR:
1.249, 95%CI: 1.002-1.555). Atmultivariate analysis, independent predictor
of mortality was logEuroscore (p<0.035, OR: 1.058, 95%CI: 1.004-1.114).
CONCLUSIONS Direct TAVI is safe and comparable outcomes are
achieved with the current practice of TAVI with balloon aortic val-
vuloplasty. Further studies are necessary to assess the long-term
mortality and effect on PVL of direct TAVI.
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BACKGROUND Transcutaneous aortic valve implantation (TAVI)
signiﬁcantly improves the prognosis of inoperable patients with severe
aortic stenosis and appears to be equivalent to surgery in high-risk
patients. However, limitations of ﬁrst-generation devices regarding
repositioning and optimization of placement can result in complica-
tions and hence increase mortality. Therefore, it was the aim of this
study to evaluate the performance of a resheathable and repositionable
self-expanding TAVI system in high risk patients with aortic stenosis.
METHODS This prospective, single arm, multicentre study evaluated
the safety and efﬁcacy of the PorticoTM Transcatheter Aortic Valve
Implantation System. Between March 2012 and April 2014 102 patients
(97% Female; Mean Age: 845 years; STS Score: 6.23.5, logistic
EuroScore: 16.77.5 %) were treated at 7 sites in the UK, and Germany
using the 18F Portico Delivery System with a 23 or 25mm Portico
Valve. Patients were followed post procedure at 30, 90, 180 days and
1 year. Adverse events were categorized by VARC deﬁnitions and
adjudicated by an independent events committee. Echocardiography
was evaluated by an independent laboratory.
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patients. Total procedural time was 4019 min, total implant time
1312 min, and ﬂuoroscopy time 197 min. An average of 19276 ml of
contrast were used during the implant procedure. Resheathing was
used in 24 patients (23%) and was successful in all instances. Average
implant depth was 6.1mm. TAVI resulted in a signiﬁcant decrease in
mean gradient from 4514 mmHg at baseline to 94 mmHg at 30 days
and an increase in aortic valve area from 0.60.2 cm2 at baseline to
1.70.4 cm2 at 30 days, respectively in the absence of signiﬁcant
postprocedural aortic regurgitation. This was associated with a signif-
icant improvement in the functional status as determined by a decline
in the New York Heart Association class. Rate of all cause of death was
2.9 and 11.8%, of cardiovascular death 2.9 and 7.8%, acute kidney injury
stage 3 2.0 and 3.9%, life-threatening or disabling bleeding 3.9 and
3.9%, disabling stroke 2.9 and 4.9%, non-disabling stroke 1 and 2%,
major vascular complications 5.9 and 6.9% at 30 days and 1 year
respectively. Implantation of a new pacemaker was required in 9.8%
and 10.8% of the patients at 30 days and 1 year, respectively.
CONCLUSIONS The novel Portico Transcatheter Aortic Valve allows
for safe repositioning and optimization of the device position. The
functional and symptomatic outcomes up to the 12 months follow
appear to support the efﬁcacy and safety of the device.
CATEGORIES STRUCTURAL: Valvular Disease: Aortic
TCT-694
“Rural” United States Experience of Incorporation of a Technologically
Advanced and Procedurally Complex Cardiovascular Program – The
Sanford Trans-catheter Aortic Valve Replacement Experience
Amol Raizada,1 Tom P. Stys,2 Adam Stys,2 Jamal Dodin,1
Terezia Petraskova,1 Maria Molga1
1University of South Dakota, Sioux Falls, SD; 2Sanford Heart Hospital,
Sioux Falls, SD
BACKGROUND The need for trans-catheter aortic valve replacement
(TAVR) coverage in a large geographical region that is sparsely popu-
lated poses peculiar challenges, especially related to low volumes of
operations both at institutional and operator level, coupled with the
need to provide these services to patients within reasonable proximity
to where they live. We compared the TAVR data at Sanford Heart
Hospital in Sioux Falls, South Dakota to the national registry data with
the aim of looking at differences in TAVR outcomes in a “rural” setting.
METHODS We analyzed the data of the ﬁrst 52 patients that underwent
TAVR at Sanford Medical Center between September 2012 and June
2014. Once severe symptomatic aortic stenosis was conﬁrmed and the
patient deemed to be either inoperable or high-risk for surgical aortic
valve replacement, they were screened for TAVR eligibility. Trans-
esophageal echocardiogram and CT-angiogram of chest, abdomen, and
pelvis were used for anatomic assessment prior to the procedure. As in
the national registry, our endpoint deﬁnitions were harmonized with
the Valve Academic Research Consortium (VARC) and VARC-2 deﬁni-
tions for stroke, transient ischemic attack, aortic valve reintervention,
major bleeding, and major vascular complications. Our data was
compared to outcomes noted for the national TAVR registry.
RESULTS As in the national registry, majority of Sanford TAVR patient
procedures were performed through femoral access (73%). In-hospital
outcomes revealed fewer cases of death from any cause, cardiac arrest,
myocardial infarction, renal failure. Median length of hospital stay
were also better compared to the national data (Table 1). Thirty day
outcomes of Sanford TAVR program compared to the registry showed
lower all cause death (1.9% vs. 7.6%), stroke (1.9% vs.2.8%) and need for
aortic valve reintervention (0% vs. 0.5%). Improvement in NYHA class
was seen in 84.6 % cases at Sanford compared to 72.4% in the registry.
Statistical analysis did not suggest a signiﬁcant difference in these
outcomes, except in the incidence of cardiac arrest.
CONCLUSIONS The Sanford data showed high quality outcomes for
the TAVR program implemented in rural United States. Although the
p-value for these outcome measures did not attain statistical signiﬁ-
cant, likely due to the small sample size of our patients, the results
were deﬁnitely comparable if not better than the national data. This
data rationalizes the feasibility of developing advanced health ser-
vices in rural areas of the country which may lead to better access and
utilization of health care resources.Table 1In-hospital outcome Sanford (n[52)National Registry
(n[7710) p-valueDeath (Any cause) 0 (0%) 427 (5.5%) 0.0512Stroke 1 (1.9%) 156 (2.0%) 0.3722Cardiac arrest 0 (0 %) 447 (5.8%) 0.0443TIA 0 (0 %) 28 (0.4%) 0.8271Myocardial infarction 0 (0 %) 56 (0.7%) 0.6836New onset atrial ﬁbrillation 6 (11.5%) 460 (6.0%) 0.0540Renal failure needing dialysis 0 (0%) 145 (1.9%) 0.3714Creatinine>3 0 (0%) 276 (3.8%) 0.1493VARC major bleeding 2 (3.8%) 267 (3.5%) 0.2740New permanent pacemaker 4 (7.69%) 509 (6.6%) 0.1945Major vascular injury 2 (3.8%) 493 (6.4%) 0.1992Device success 50 (96%) 7069 (92%) 0.1191Transapical site access complications 0 (0%) 61 (0.8%) 0.6607Median stay of length (days) 4 6Live hospital discharges 52 (100%) 7286 (94.5%)CATEGORIES OTHER: Political, International and Societal Issues
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BACKGROUND Transcatheter aortic valve replacement (TAVR) is
increasingly being performed in cardiac catheterization laboratories
using transthoracic echocardiography (TTE) to guide valve deploy-
ment. This minimalist approach has been shown to be less costly, and
associated with procedural outcomes equivalent to the standard
approach that uses transesophageal echocardiography (TEE) guidance
for valve deployment. The risk of paravalvular leak (PVL) remains a
concern. Whether TTE-guided valve deployment is associated with a
higher incidence of paravalvular leak (PVL) is unclear.
METHODS Medical records of 474 patients (mean age 828, 58%
male, 86% Caucasians) who underwent TAVR with Edwards SAPIEN
(60%) or SAPIEN-XT (40%) at Emory University Hospital from 2007 to
2014 via the transfemoral approach were reviewed and compared. 267
patients underwent TAVR in the cardiac catheterization laboratory
under TTE guidance, while 207 patients underwent TAVR using con-
ventional, TEE-guided approach in the hybrid operating room. Clin-
ical characteristics, procedural outcomes and echocardiograms at
baseline and follow-up were compared.
RESULTS Patients who underwent TTE-guided TAVR had a lower STS
score (9.24.4% versus 11.27.8%, P¼0.004), higher EF (5313% versus
4813%, P¼0.004) and were more likely to have received a SAPIEN-XT
valve (47% versus 33% P¼0.007) compared to those with conventional
TEE-guided approach. The incidence of at least mild post-TAVR PVL
was lower in the minimalist approach compared to the conventional
one (29% versus 37% respectively, P¼0.069). In a binary logistic
regression model including demographics, valve type and size, TAVR
approach, year of procedure and STS score, only valve size (OR 0.80,
95% CI [0.68,0.94]), male gender (OR 3.0, 95% CI [1.6,5.5]) were sig-
niﬁcant predictors of post-TAVR PVL. Procedure year, reﬂective of
experience was close to statistical signiﬁcance (OR 0.83, 95% CI
[0.68,1.01]). Neither valve type (P¼0.482) nor TAVR approach
(P¼0.368) were independently associated with post-TAVR PVL.
CONCLUSIONS The minimalist TAVR approach was not associated with
increased PVL. TTE-guided TAVR is likely safe and cost-effective. Multi-
center studieswith larger sample sizesare required to conﬁrmtheseﬁndings.
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